Hung-Ching Lin

Hung-Ching Lin

Auto-generated profile, based on publicly available information

Hung-Ching Lin

Department of Otolaryngology Head and Neck Surgery, MacKay Memorial Hospital, Taipei, Taiwan ";" Department of Audiology and Speech Language Pathology, MacKay Medical University, New Taipei City, Taiwan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2007 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
Bolajoko OlusanyaBolajoko Olusanya
Bolajoko Olusanya
DSDe Wet Swanepoel
De Wet Swanepoel
MCMônica J Chapchap
Mônica J Chapchap
SCSalvador Castillo
Salvador Castillo
HHHamed Habib
Hamed Habib
BMBradley McPherson
Bradley McPherson
Background: Early detection of infants with permanent hearing loss through infant hearing screening is recognised and routinely offered as a vital component of early childhood care in developed countries. This article investigates the initiatives and progress towards early detection of infants with hearing loss in developing countries against the backdrop of the dearth of epidemiological data from this region.Methods: A cross-sectional, descriptive study based on responses to a structured questionnaire eliciting information on the nature and scope of early hearing detection services; strategies for financing services; parental and professional attitudes towards screening; and the performance of screening programmes. Responses were complemented with relevant data from the internet and PubMed/Medline.Results: Pilot projects using objective screening tests are on-going in a growing number of countries. Screening services are provided at public/private hospitals and/or community health centres and at no charge only in a few countries. Attitudes amongst parents and health care workers are typically positive towards such programmes. Screening efficiency, as measured by referral rate at discharge, was generally found to be lower than desired but several programmes achieved other international benchmarks. Coverage is generally above 90% but poor follow-up rates remain a challenge in some countries. The mean age of diagnosis is usually less than six months, even for community-based programmes.Conclusion: Lack of adequate resources by many governments may limit rapid nationwide introduction of services for early hearing detection and intervention, but may not deter such services altogether. Parents may be required to pay for services in some settings in line with the existing practice where healthcare services are predominantly financed by out-of-pocket spending rather than public funding. However, governments and their international development partners need to complement current voluntary initiatives through systematic scaling-up of public awareness and requisite manpower development towards sustainable service capacities at all levels of healthcare delivery.

1 November 2005 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
HLHung‐Ching Lin
Hung‐Ching Lin
MSMin‐Tsan Shu
Min‐Tsan Shu
KLKuo‐Sheng Lee
Kuo‐Sheng Lee
GHGuan‐Min Ho
Guan‐Min Ho
TFTzu‐Yu Fu
Tzu‐Yu Fu
GLGrace Lin
Grace Lin

1 September 2007 in Otology & Neurotology
Verified
Journal Article
Closed access
HLHung-Ching Lin
Hung-Ching Lin
MSMin-Tsan Shu
Min-Tsan Shu
KLKuo-Sheng Lee
Kuo-Sheng Lee
HLHuang-Yu Lin
Huang-Yu Lin
GLGrace Lin
Grace Lin
To compare the initial referral rate, the accurate identification rate of congenital hearing loss, and the cost between one step with transient evoked otoacoustic emissions (TEOAEs), two steps with TEOAE and automated auditory brainstem response (AABR), and one step with AABR in newborn hearing screening program. The aim of this study is to compare their efficacy between our three different protocols and to see which one is most cost-effective. From November 1998 to April 2006, 25,588 healthy newborns were screened for hearing loss in Mackay Memorial Hospital, Taipei. In the periods from November 1998 to January 2004, from February 2004 to February 2005, and from March 2005 to April 2006, the screening tools used were TEOAE alone (n = 18,260), TEOAE plus AABR (n = 3,540), and AABR (n = 3,788), respectively. A statistically significant decrease in referral rate was achieved in the group using AABR as screening tools when compared with TEOAE plus AABR and TEOAE alone (0.8 versus 1.6 versus 5.8%). The accurate identification rate of congenital hearing loss was 0.42% in AABR protocol, 0.25% in TEOAE and AABR protocol, and 0.45% in TEOAE protocol, which was not statistically significant. The total direct costs (including predischarge screening and postdischarge follow-up costs) per screening were US $10.04 for the program using TEOAE alone, US $8.60 for TEOAE plus AABR, and US $7.33 for AABR. The intangible cost (parental anxiety) was much higher in the earlier program due to higher referral rate. In the efficacy of the hearing screening program using the one-step TEOAE, two-step TEOAE and AABR, and one-step AABR programs, the latter significantly decreased the referral rate from 5.8, to 1.6, and to 0.8%. No significant difference was noted between their accurate identification rates of congenital hearing loss. The total costs, including expenditures and intangible cost, were much lower in the protocol with AABR due to reduction in false positives.

Verified
Journal Article
Open access
PDF file
Stella Chin-Shaw TsaiStella Chin-Shaw Tsai
Stella Chin-Shaw Tsai
KYKuender D. Yang
Kuender D. Yang
KCKuang-Hsi Chang
Kuang-Hsi Chang
Frank Cheau-Feng LinFrank Cheau-Feng Lin
Frank Cheau-Feng Lin
RCRuey-Hwang Chou
Ruey-Hwang Chou
ICIng-Ming Chiu
Ing-Ming Chiu
Umbilical cord-derived mesenchymal stromal cells (UCMSCs) have potential applications in regenerative medicine. UCMSCs have been demonstrated to repair tissue damage in many inflammatory and degenerative diseases. We have previously shown that UCMSC exosomes reduce nerve injury-induced pain in rats. In this study, we characterized UCMSC exosomes using RNA sequencing and proteomic analyses and investigated their protective effects on cisplatin-induced hearing loss in mice. Two independent experiments were designed to investigate the protective effects on cisplatin-induced hearing loss in mice: (i) chronic intraperitoneal cisplatin administration (4 mg/kg) once per day for 5 consecutive days and intraperitoneal UCMSC exosome (1.2 μg/μL) injection at the same time point; and (ii) UCMSC exosome (1.2 μg/μL) injection through a round window niche 3 days after chronic cisplatin administration. Our data suggest that UCMSC exosomes exert protective effects in vivo. The post-traumatic administration of UCMSC exosomes significantly improved hearing loss and rescued the loss of cochlear hair cells in mice receiving chronic cisplatin injection. Neuropathological gene panel analyses further revealed the UCMSC exosomes treatment led to beneficial changes in the expression levels of many genes in the cochlear tissues of cisplatin-injected mice. In conclusion, UCMSC exosomes exerted protective effects in treating ototoxicity-induced hearing loss by promoting tissue remodeling and repair.

17 October 2015 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
PSPeijen Su
Peijen Su
YLYun-Chih Liu
Yun-Chih Liu
HLHung-Ching Lin
Hung-Ching Lin

30 January 2002 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
HLHung-Ching Lin
Hung-Ching Lin
MSMin-Tsan Shu
Min-Tsan Shu
KCKe-Chang Chang
Ke-Chang Chang
SBSharon M. Bruna
Sharon M. Bruna